









Markets
/
Stocks
/
nasdaq-obio
/

Orchestra Biomed Holdings Inc

OBIO

3.910USD

+0.200+5.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

220.78MMarket Cap

LossP/E TTM



Orchestra Biomed Holdings Inc

3.910

+0.200+5.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Orchestra Biomed Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.43.In the medium term, the stock price is expected to remain stable.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Orchestra Biomed Holdings Inc's Score

Industry at a Glance

Industry Ranking

108 / 205

Overall Ranking

285 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Orchestra Biomed Holdings Inc Highlights

StrengthsRisks

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.64M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.64M.

Overvalued

The company’s latest PE is -2.18, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 22.07M shares, increasing 9.49% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.14K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.02.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.429

Target Price

+253.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Orchestra Biomed Holdings Inc is 5.78, ranking 186 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 861.00K, representing a year-over-year decrease of 12.77%, while its net profit experienced a year-over-year decrease of 35.02%.

Score

Industry at a Glance

Previous score

5.78

Change



Financials

7.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.61

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Orchestra Biomed Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Orchestra Biomed Holdings Inc is 8.38, ranking 23 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.18, which is -41.02% below the recent high of -1.28 and -659.72% above the recent low of -16.54.

Score

Industry at a Glance

Previous score

8.38

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 12.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.429

Target Price

+253.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Orchestra Biomed Holdings Inc

OBIO

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Orchestra Biomed Holdings Inc is 5.95, ranking 168 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.78 and the support level at 3.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.77

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Sell

RSI(14)

46.168

Neutral

STOCH(KDJ)(9,3,3)

47.924

Neutral

ATR(14)

0.326

High Vlolatility

CCI(14)

-52.807

Neutral

Williams %R

50.544

Neutral

TRIX(12,20)

-0.594

Sell

StochRSI(14)

68.499

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.904

Buy

MA10

3.878

Buy

MA20

4.083

Sell

MA50

4.358

Sell

MA100

3.894

Buy

MA200

3.381

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Orchestra Biomed Holdings Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 39.09%, representing a quarter-over-quarter increase of 10.01%. The largest institutional shareholder is The Vanguard, holding a total of 1.60M shares, representing 2.84% of shares outstanding, with 16.75% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

8.31M

Medtronic PLC

5.87M

Perceptive Advisors LLC

5.29M

Tasso Partners, LLC

2.85M

The Vanguard Group, Inc.

Star Investors

1.48M

+28.04%

Alyeska Investment Group, L.P.

1.37M

Pathstone

1.01M

HSAC 2 Holdings LLC

955.71K

-78.08%

Affinity Asset Advisors LLC

727.27K

Knoll Capital Management, LLC

455.13K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Orchestra Biomed Holdings Inc is 2.78, ranking 146 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.